Status:
COMPLETED
Psilocybin for Treatment of Obsessive Compulsive Disorder
Lead Sponsor:
University of Arizona
Conditions:
Obsessive-compulsive Disorder (OCD)
Eligibility:
All Genders
18-65 years
Phase:
PHASE1
Brief Summary
This study will evaluate whether psilocybin, a hallucinogenic drug, improves symptoms of obsessive compulsive disorder (OCD), whether it is safely tolerated as treatment of OCD, and will investigate t...
Detailed Description
The study seeks to improve our ability to treat and improve the lives of people who have obsessive-compulsive disorder (OCD) by exploring the benefits of psilocybin, a mind-altering drug that changes ...
Eligibility Criteria
Inclusion
- Have moderate to severe OCD (DSM-5) after diagnostic interview using the Structured Clinical Interview for DSM-5 Research Version (SCID-R).
- Failed at least one adequate attempted routine care treatment.
- Considered safe for independent living
Exclusion
- Concurrent psychosis, active substance use disorder, or a personal history of psychosis.
- Medical illness based on physical examination and routine blood testing that may complicate cardiovascular safety or drug metabolism or excretion, such as uncontrolled hypertension, severe cardiac disease, or kidney or liver failure.
- Unstable Chronic Obstructive Pulmonary Disease (COPD) or severe sleep apnea
- Psychiatric comorbidity that may represent an acute risk to their own or others' safety.
- Subjects may not be using antidepressant medication for OCD for at least two weeks before receiving study drug, and they cannot require any sedative, narcotic, or neuroleptic medications on a regular basis. Any of these medications they have taken should have been stopped long enough in the past to allow for their elimination and safe withdrawal prior to starting administration of the study drug. The specific time required will be dependent on the medication the patient was previously receiving.
- Women who are pregnant, breastfeeding, or unwilling/unable to practice medically acceptable birth control during the study.
- Allergy to lorazepam.
Key Trial Info
Start Date :
January 2 2019
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 30 2023
Estimated Enrollment :
15 Patients enrolled
Trial Details
Trial ID
NCT03300947
Start Date
January 2 2019
End Date
December 30 2023
Last Update
August 30 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Arizona
Tucson, Arizona, United States, 85724